CytomX Therapeutics
Early-stage biotechnology company developing probodies, proteolytically-activated antibodies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $100m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (31 %) | (24 %) | 90 % | 36 % | (32 %) | (47 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (120 %) | (191 %) | (4 %) | 19 % | 23 % | (9 %) | (27 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (120 %) | (187 %) | (1 %) | 23 % | 8 % | (88 %) | (108 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 164 % | 210 % | 77 % | 60 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
CytomX Therapeutics, Inc., based in South San Francisco, California, is dedicated to revolutionizing cancer treatment through its innovative Probody® therapeutic platform. The company operates in the biotechnology sector, focusing on developing safer and more effective cancer therapies. CytomX serves a diverse patient population, aiming to bring scientific advancements to those in need. The business model revolves around advancing a broad pipeline of clinical-stage programs, with five currently in clinical trials and more in development. Revenue is generated through the development and potential commercialization of these therapies. The company emphasizes a culture of integrity, collaboration, and diversity, striving to maintain high standards and foster an inclusive workplace.
Keywords: cancer treatment, Probody® platform, clinical-stage programs, biotechnology, patient-focused, therapeutic development, South San Francisco, diversity, equity, inclusion.
Tech stack
Investments by CytomX Therapeutics
Edit